Sign In

Login

Password

Forgot Password ? Sign Up

Endothelial cell anergy (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Endothelial cell anergy" in English language version.

refsWebsite
Global rank English rank
13nih.gov
4th place
4th place
8doi.org
2nd place
2nd place
4semanticscholar.org
11th place
8th place

doi.org

  • Huinen ZR, Huijbers EJ, van Beijnum JR, Nowak-Sliwinska P, Griffioen AW (August 2021). "Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomes". Nature Reviews. Clinical Oncology. 18 (8): 527–540. doi:10.1038/s41571-021-00496-y. PMID 33833434. S2CID 233187995.
  • Dudley AC, Griffioen AW (April 2023). "Pathological angiogenesis: mechanisms and therapeutic strategies". Angiogenesis. 26 (3): 313–347. doi:10.1007/s10456-023-09876-7. PMC 10105163. PMID 37060495.
  • Griffioen AW, Damen CA, Blijham GH, Groenewegen G (July 1996). "Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium". Blood. 88 (2): 667–673. doi:10.1182/blood.V88.2.667.bloodjournal882667. PMID 8695814. S2CID 35620015.
  • Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK (May 2018). "Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges". Nature Reviews. Clinical Oncology. 15 (5): 325–340. doi:10.1038/nrclinonc.2018.29. PMC 5921900. PMID 29508855.
  • Dings RP, Vang KB, Castermans K, Popescu F, Zhang Y, Oude Egbrink MG, et al. (May 2011). "Enhancement of T-cell-mediated antitumor response: angiostatic adjuvant to immunotherapy against cancer". Clinical Cancer Research. 17 (10): 3134–3145. doi:10.1158/1078-0432.CCR-10-2443. PMC 4242153. PMID 21252159.
  • Nowak-Sliwinska P, van Beijnum JR, Griffioen CJ, Huinen ZR, Sopesens NG, Schulz R, et al. (May 2023). "Proinflammatory activity of VEGF-targeted treatment through reversal of tumor endothelial cell anergy". Angiogenesis. 26 (2): 279–293. doi:10.1007/s10456-022-09863-4. PMC 10119234. PMID 36459240.
  • Khan KA, Kerbel RS (May 2018). "Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa". Nature Reviews. Clinical Oncology. 15 (5): 310–324. doi:10.1038/nrclinonc.2018.9. PMID 29434333. S2CID 4957378.
  • Huijbers EJ, Khan KA, Kerbel RS, Griffioen AW (January 2022). "Tumors resurrect an embryonic vascular program to escape immunity". Science Immunology. 7 (67): eabm6388. doi:10.1126/sciimmunol.abm6388. PMID 35030032. S2CID 245933926.

nih.gov

pubmed.ncbi.nlm.nih.gov

  • Huinen ZR, Huijbers EJ, van Beijnum JR, Nowak-Sliwinska P, Griffioen AW (August 2021). "Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomes". Nature Reviews. Clinical Oncology. 18 (8): 527–540. doi:10.1038/s41571-021-00496-y. PMID 33833434. S2CID 233187995.
  • Dudley AC, Griffioen AW (April 2023). "Pathological angiogenesis: mechanisms and therapeutic strategies". Angiogenesis. 26 (3): 313–347. doi:10.1007/s10456-023-09876-7. PMC 10105163. PMID 37060495.
  • Griffioen AW, Damen CA, Martinotti S, Blijham GH, Groenewegen G (March 1996). "Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors". Cancer Research. 56 (5): 1111–1117. PMID 8640769.
  • Griffioen AW, Damen CA, Blijham GH, Groenewegen G (July 1996). "Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium". Blood. 88 (2): 667–673. doi:10.1182/blood.V88.2.667.bloodjournal882667. PMID 8695814. S2CID 35620015.
  • Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK (May 2018). "Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges". Nature Reviews. Clinical Oncology. 15 (5): 325–340. doi:10.1038/nrclinonc.2018.29. PMC 5921900. PMID 29508855.
  • Dings RP, Vang KB, Castermans K, Popescu F, Zhang Y, Oude Egbrink MG, et al. (May 2011). "Enhancement of T-cell-mediated antitumor response: angiostatic adjuvant to immunotherapy against cancer". Clinical Cancer Research. 17 (10): 3134–3145. doi:10.1158/1078-0432.CCR-10-2443. PMC 4242153. PMID 21252159.
  • Nowak-Sliwinska P, van Beijnum JR, Griffioen CJ, Huinen ZR, Sopesens NG, Schulz R, et al. (May 2023). "Proinflammatory activity of VEGF-targeted treatment through reversal of tumor endothelial cell anergy". Angiogenesis. 26 (2): 279–293. doi:10.1007/s10456-022-09863-4. PMC 10119234. PMID 36459240.
  • Khan KA, Kerbel RS (May 2018). "Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa". Nature Reviews. Clinical Oncology. 15 (5): 310–324. doi:10.1038/nrclinonc.2018.9. PMID 29434333. S2CID 4957378.
  • Huijbers EJ, Khan KA, Kerbel RS, Griffioen AW (January 2022). "Tumors resurrect an embryonic vascular program to escape immunity". Science Immunology. 7 (67): eabm6388. doi:10.1126/sciimmunol.abm6388. PMID 35030032. S2CID 245933926.

ncbi.nlm.nih.gov

semanticscholar.org

api.semanticscholar.org

  • Huinen ZR, Huijbers EJ, van Beijnum JR, Nowak-Sliwinska P, Griffioen AW (August 2021). "Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomes". Nature Reviews. Clinical Oncology. 18 (8): 527–540. doi:10.1038/s41571-021-00496-y. PMID 33833434. S2CID 233187995.
  • Griffioen AW, Damen CA, Blijham GH, Groenewegen G (July 1996). "Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium". Blood. 88 (2): 667–673. doi:10.1182/blood.V88.2.667.bloodjournal882667. PMID 8695814. S2CID 35620015.
  • Khan KA, Kerbel RS (May 2018). "Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa". Nature Reviews. Clinical Oncology. 15 (5): 310–324. doi:10.1038/nrclinonc.2018.9. PMID 29434333. S2CID 4957378.
  • Huijbers EJ, Khan KA, Kerbel RS, Griffioen AW (January 2022). "Tumors resurrect an embryonic vascular program to escape immunity". Science Immunology. 7 (67): eabm6388. doi:10.1126/sciimmunol.abm6388. PMID 35030032. S2CID 245933926.